Sabine Uhles

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

Journal: Frontiers in pharmacology

Published: May 01, 2024

Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion.

Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion.

Journal: Frontiers in cellular neuroscience

Published: March 23, 2023

Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells.

Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 08, 2020

Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.

Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.

Journal: EMBO molecular medicine

Published: May 02, 2019

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome.

Journal: ACS chemical biology

Published: November 20, 2018

Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.

Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.

Journal: Journal of translational medicine

Published: April 30, 2018

DDR1 role in fibrosis and its pharmacological targeting.

DDR1 role in fibrosis and its pharmacological targeting.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: February 23, 2018

Incretin-like effects of small molecule trace amine-associated receptor 1 agonists.

Incretin-like effects of small molecule trace amine-associated receptor 1 agonists.

Journal: Molecular metabolism

Published: August 26, 2015

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Journal: Nature medicine

Published: July 24, 2014

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Journal: Science translational medicine

Published: November 01, 2013

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.

Journal: Diabetes, obesity & metabolism

Published: May 15, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026